CYTOSORBENTS CORP

CTSO stock represents shares of Cytosorbents Corporation, a commercial-stage medical device company. The company develops and markets blood purification technologies designed to treat life-threatening conditions by removing harmful substances from the blood. CTSO trades on the Nasdaq Capital Market under the ticker symbol CTSO. Investors tracking the stock are typically following a small-cap healthcare company whose performance is tied to product adoption, clinical evidence, and regulatory developments rather than to broad consumer or industrial trends.

Recent performance for CTSO depends on evolving market conditions, company announcements, and investor sentiment, so the exact figures change frequently. The stock has historically shown the volatility common to small-cap medical device companies, with price moves often linked to clinical trial updates, regulatory decisions, and quarterly financial results. For the most current performance data, including recent daily and weekly percentage changes, refer to the live price chart and performance section displayed on this CTSO page.

Evaluating CTSO's valuation usually involves examining several metrics together, because unprofitable or early-stage medical device companies often have limited or negative earnings. Useful measures may include price-to-sales, price-to-book, enterprise value relative to revenue, and cash position compared with market capitalization. Investors also consider the potential market size for the company's products, reimbursement progress, and clinical milestones. Because these factors change over time, compare the latest reported financials with CTSO's current market value shown on this page.

CTSO can potentially trade outside regular U.S. market hours through pre-market and after-hours sessions, though liquidity is typically much lower than during the standard trading day. Extended-hours trading may involve wider bid-ask spreads, greater price volatility, and reduced order execution certainty. Not all brokers offer this capability, and available session times can vary by brokerage. Investors should check their broker's specific extended-hours policies and consider the risks before placing orders for CTSO outside regular hours.

For CTSO, key financial metrics include revenue growth, gross margin, operating expenses, net loss or income, and cash and cash equivalents. Because Cytosorbents operates in the medical device space, product revenue trends, reimbursement developments, and research and development spending can be particularly relevant. Investors may also review shares outstanding, cash burn rate, and any debt obligations to assess financial flexibility. These figures are reported in the company's quarterly and annual filings, which should be compared with the latest CTSO data shown on this page.

CTSO carries risks common to small-cap medical device companies, including dependence on regulatory approvals, clinical trial outcomes, product adoption by hospitals, and reimbursement decisions. The company may face competition, intellectual property challenges, supply chain constraints, and the need for additional capital. Its financial results can be volatile, and the stock price may be sensitive to news about trials, earnings, or financing. These factors can affect both the company's operations and the trading price of CTSO shares.